AstraZeneca's human monoclonal antibody Imfinzi (durvalumab), when combined with standard-of-care Bacillus Calmette-Guérin ...

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

AstraZeneca aims to widen the pool of bladder cancer patients who can be treated with its PD-L1 inhibitor Imfinzi after the drug demonstrated benefits in those with a higher-risk form of non-muscle | ...

The approval in MIBC was based on positive results from the phase 3 NIAGARA trial, in which the Imfinzi regimen demonstrated ...

AstraZeneca’s Imfinzi is part of a comprehensive development programme, being evaluated both as a standalone and in conjunction with other therapies for various cancers. Credit: Michael ...

AstraZeneca PLC (LSE/STO/Nasdaq:LON:AZN) has announced positive results from the POTOMAC Phase III trial, which evaluated Imfinzi (durvalumab) in combination with Bacillus Calmette-Guérin (BCG ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

"The positive results for Imfinzi in the Potomac trial represent a significant advance that will potentially allow more patients with early-stage bladder cancer to benefit from this important ...